| Revenue guidance | 35.0% → 50.0% Raised by 15.0 percentage points |
|---|---|
| Management target | Revenue 50.0% Next 3 years |
| Revenue growth | 19.62% YoY growth driven by diagnostic network expansion. |
|---|---|
| Margins | Structural expansion targeting 40% EBITDA margin as pharmacy segment exits. |
| Demand visibility | Strong traction in Tier 2/3 markets for preventive health checkups. |
| Management confidence | Aggressive and bullish on diagnostic transition and franchise model. |
Growth
Revenue grew 19.62% YoY to ₹82.26 Cr. B2B business surged 94% while diagnostic EBITDA reached 36.57%.
Outlook
Management raised revenue growth guidance to 50% YoY for next 3 years via diagnostic expansion.
Risks
Pharmacy divestment creates short-term revenue vacuum. Heavy franchise expansion risks brand dilution and quality control issues.
Earnings Call Transcript filed with NSE, NSE: CHANDAN. Summary written with AI assistance from the document.
Chandan Healthcare Ltd: key numbers
- Share price
- ₹241.20
- Market cap
- ₹604.3 Cr
- Revenue (annual)
- ₹276.4 Cr
- Net profit (annual)
- ₹28.55 Cr
- P/E (TTM)
- 21.2×Sector 57.8×
- Promoter holding
- 49.61%+0.06% QoQ
- FII holding
- 0.01%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Chandan Healthcare Ltd
All →Chandan Healthcare Capacity Expansion
Chandan Healthcare scaled its diagnostic franchise network to 500+ centres, reaching a total of 568+ centres. It targets 1,000 centres by FY27-end and 3,000 in two years.
- diagnostic franchise collection centres
- 500 franchise centres
Chandan Healthcare Results Correction
Chandan Healthcare clarified to NSE it has one reportable segment, explaining the omission of segment-wise details in its Q4 FY27 financial results.
Chandan Healthcare Capital Structure Change
Chandan Healthcare Limited has allotted 5,99,998 equity shares upon conversion of fully convertible warrants, aggregating to ₹14.04 Crore.
- Value
- ₹14.04 Cr
Chandan Healthcare Board Meeting Outcome
Chandan Healthcare Ltd's board approved the appointment of an Independent Director, ratified cost auditor remuneration, and recommended varying the objects for utilising unutilised warrant proceeds.
Chandan Healthcare Investor Presentation: Key Takeaways
Chandan Healthcare reported strong Q1 FY27 results with 19.62% YoY revenue growth and 42.27% EBITDA growth, driven by expansion into 15 states and diversified B2C, B2B, and B2G segments.
Chandan Healthcare Q1 FY27 Results: Net Profit ₹7.5 Cr, Up 29.3% YoY
Chandan Healthcare Ltd reported revenue from operations of ₹80.9 Cr (+19.1% YoY) and net profit of ₹7.5 Cr (+29.3% YoY) for Q1 FY27.
- Key figure
- Net profit ₹7.5 Cr · +29.3% YoY